Abstract:Background: Tuberculosis drug-induced liver injury (TB-DILI) is a common and potentially severe adverse drug reaction leading to treatment interruption and treatment failure. The real-world preventive effectiveness of hepatoprotective agents for DILI is not well described. The aim of the study was to evaluate the patterns of prophylactic therapies in real-world settings and risks of DILI among adult TB patients without known risk factors for DILI. Methods: This is a population-based retrospective cohort study of patients receiving first-line anti-tuberculosis drugs in the Chinese Center for Disease Control and Prevention (CDC) TB registry linked to the Ningbo Regional Health Care Database (NRHCD) between 2015 and 2020. The primary exposure was any use of chemopreventive agents including silymarin and/or glycyrrhetinic acid during the 30-day period prior to TB diagnosis (index date). The main outcome measure was the occurrence of newly onset DILI following TB treatment. Eligible patients were followed until the earliest of any DILI, treatment discontinuation, death, or end of the study period (30 June 2020). Marginal structural competing risk models and Cox models via inverse probability treatment weights using high-dimensional propensity scores were used to estimate subdistribution hazard risks (SHR) and 95% confidence intervals (CIs) for DILI risks, with adjustment for age, sex, TB-related characteristics, and comorbidities. Results: We identified a cohort of 6,743 adult patients with TB (mean age of 47.1 [SD 18.7] years; 65.80% male), of whom 2,886 (42.8%) patients received hepatoprotective agents. A total of 895 DILI events and 111 all-cause death events without DILI were observed over a median follow-up of 367 days post-TB diagnosis. The incidence rates of composite outcomes combining DILI and all-cause mortality were 248.9 and 222.3 per 1,000 person-years in the hepatoprotective agent exposed and unexposed groups (relative hazard ratio 1.35, 95% CI 1.11–1.64), respectively. The incidence rates of DILI were 223.7 and 196.1 per 1,000 person-years in the hepatoprotective agent exposed and unexposed groups (relative hazard ratio 1.38, 95% CI 1.12–1.71), respectively. Patients with any chemopreventive agent use had comparable liver function changes as evidenced by laboratory tests. Conclusion: A non-trivial number of adult patients received chemopreventive agents for TB-DILI. However, prophylactic utilization of hepatoprotective agents was not associated with a reduction in TB-DILI risks.

[Pharmacoeconomic Profiles of Four Hepatoprotective Drugs Used for the Treatment of Drug-Induced Liver Injury].

An Analysis of the Efficacy and Safety of Compound Glycyrrhizin Injections in the Treatment of Drug-Induced Liver Injury Using a Nationwide Database.

Causal Evaluation of Post-Marketing Drugs for Drug-induced Liver Injury from Electronic Health Records*

Network meta-analysis of different liver protective drugs in the treatment of drug-induced liver injury

Bicyclol for the Treatment of Drug-Induced Liver Injury: a Propensity Score Matching Analysis Using a Nationwide Inpatient Database

Efficacy and safety of bicyclol for treating patients with idiosyncratic acute drug‐induced liver injury: A multicenter, randomized, phase II trial

Efficacy of different therapeutic modalities for patients with acute-on-chronic liver failure induced by hepatitis B

Pharmacotherapies for Drug-Induced Liver Injury: A Current Literature Review

Efficacy and safety of bicyclol for treating patients with antituberculosis drug-induced liver injury

[The Clinical Features and Prognosis of Drug-Induced Liver Disease].

A new prognostic model for drug-induced liver injury especially suitable for Chinese population

Metabolomics and Cytokine Analysis for Identification of Severe Drug-Induced Liver Injury.

Effectiveness of Prophylactic Use of Hepatoprotectants for Tuberculosis Drug-Induced Liver Injury: A Population-Based Cohort Analysis Involving 6,743 Chinese Patients

Therapeutic Potential of Nutraceuticals against Drug-Induced Liver Injury

Drug-induced liver injury and anti-hepatotoxic effect of herbal compounds: a metabolic mechanism perspective

Clinical features and prognosis of drug -induced liver injury: An analysis of 95 cases

Hospital Admissions for Drug-Induced Liver Injury: Clinical Features, Therapy, and Outcomes

Utility of human cytochrome P450 inhibition data in the assessment of drug-induced liver injury

Clinical features of drug-induced liver failure and related diagnosis and treatment strategies

Effects of Compound Anoectochilus roxburghii (Wall.) Lindl. Oral Liquid on relative metabolic enzymes and various biochemical indices in Wistar rats with isoniazid-induced liver injury

Cost-effectiveness analysis of four pharmacotherapeutic schemes for the patients with acute bleeding portal hypertensive gastropathy